Maze Therapeutics (NASDAQ:MAZE) Upgraded at Truist Financial

Truist Financial upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Wedbush upped their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday. Guggenheim increased their target price on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $58.56.

Maze Therapeutics Stock Performance

MAZE stock opened at $49.43 on Tuesday. The firm’s fifty day moving average is $45.68 and its 200 day moving average is $36.59. The firm has a market cap of $2.38 billion, a PE ratio of -2.37 and a beta of 4.47. Maze Therapeutics has a one year low of $6.71 and a one year high of $53.65.

Insider Transactions at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total value of $405,800.00. Following the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. This trade represents a 43.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 230,000 shares of company stock valued at $9,768,292.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC raised its stake in Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after purchasing an additional 2,390,713 shares during the period. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the period. Marshall Wace LLP lifted its holdings in Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after acquiring an additional 758,104 shares during the last quarter. Caligan Partners LP acquired a new stake in Maze Therapeutics during the fourth quarter worth $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new stake in Maze Therapeutics in the third quarter valued at $14,135,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.